CT-Based Lymph Node Risk Prediction for Faster Lung Cancer Staging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current lung cancer staging methods involving thoracic lymph nodes are invasive, costly, and time-consuming, leading to prolonged diagnosis-to-treatment times and increased patient anxiety, with potential metastasis during this period.
Innovation Solution
A machine learning-based approach using thoracic CT scans to predict the risk of lymph node metastasis, employing an imputation model to analyze lymph node features and a risk model to determine subject-level metastatic cancer risk, allowing for targeted diagnostic and therapeutic interventions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If invasive testing procedures (PET scanning, lymph node biopsy) are performed to accurately stage lung cancer, then measurement precision of nodal status is improved, but loss of time and patient burden increase
Solution Approach 1:
The system performs preliminary risk assessment of lymph node metastasis using machine learning analysis of the initial thoracic CT scan before committing patients to invasive staging procedures. By evaluating CT scan features and predicting nodal involvement risk in advance, the system enables clinicians to prioritize testing for high-risk patients and avoid unnecessary invasive procedures in low-risk patients, thereby reducing overall diagnosis time while maintaining accurate staging for those who need it.
2Measurement precision
If multiple invasive testing procedures are performed to determine lymph node involvement, then measurement precision of cancer staging is improved, but device complexity and procedural burden increase
Solution Approach 1:
The system extracts and analyzes relevant features directly from the existing thoracic CT scan images using machine learning algorithms to predict lymph node metastasis risk. By deriving diagnostic information from the already-acquired CT scan data without requiring additional invasive procedures, the system eliminates the need for separate PET scanning and biopsy procedures in many cases, thereby reducing procedural complexity while maintaining staging accuracy.
3Measurement precision
If invasive lymph node sampling procedures are performed, then measurement precision of nodal status is improved, but ease of operation and patient comfort worsen
Solution Approach 1:
The system introduces machine learning analysis of CT scan features as an intermediary step between initial lung nodule detection and invasive lymph node sampling. This intermediary risk assessment layer identifies which patients are most likely to benefit from invasive procedures, allowing clinicians to target biopsies only to high-risk patients while managing low-risk patients with less invasive approaches, thereby improving overall ease of operation and patient comfort.
4Reliability
If extensive clinical evaluation including PET scanning and biopsy is performed, then reliability of cancer staging is improved, but productivity and treatment throughput decrease
Solution Approach 1:
The system performs preliminary stratification of patients into high-risk and low-risk categories for lymph node metastasis using machine learning analysis of the initial CT scan. This preliminary action enables parallel processing pathways: high-risk patients proceed to comprehensive invasive staging for reliable confirmation, while low-risk patients can proceed directly to treatment based on the predictive model, thereby maintaining staging reliability for those who need it while significantly improving overall diagnostic throughput and reducing delays to treatment.
Data Source
AI summary
Disclosed herein are methods for determining a subject level risk of metastatic cancer involving the training and/or deployment of models to determine 1) a lymph node level risk of individual lymph node involvement and/or 2) a subject level risk of lymph node involvement. Thus, the methods can identify patients who are high or low risk for having nodal disease and optionally enable the guided intervention of cancer patients, for example, via treatment.